RALEIGH, N.C., July 14, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) releases, today, a summary highlighting preclinical data for DB959, its lead compound for Type 2 Diabetes (T2D) that shows promise as a therapeutic candidate with cardiovascular benefits. Mary Kay Delmedico, Ph.D., Project Leader/Program Manager, DARA BioSciences, Inc., presented the data this month at the American Diabetes Association's 69th Scientific Sessions held June 5 - 9, 2009 in New Orleans, La. and highlighted its favorable safety profile as a unique, first-in-class dual peroxisome proliferator-activated receptor (PPAR)-delta/gamma agonist without PPAR-alpha activity.
